Raymond James Financial’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.3M Buy
484,821
+12,528
+3% +$604K 0.01% 1457
2026
Q2
$27.7M Buy
472,293
+102,032
+28% +$4.28M 0.01% 1335
2026
Q1
$11.4M Sell
370,261
-14,068
-4% -$521K ﹤0.01% 1910
2025
Q4
$16.2M Buy
384,329
+187,334
+95% +$7.55M 0.01% 1585
2025
Q3
$6.76M Sell
196,995
-8,333
-4% -$239K ﹤0.01% 2233
2025
Q2
$5.55M Sell
205,328
-7,746
-4% -$224K ﹤0.01% 2308
2025
Q1
$6.32M Buy
213,074
+172,010
+419% +$6.56M ﹤0.01% 2171
2024
Q4
$1.63M Buy
+41,064
New +$1.55M ﹤0.01% 3116

Other funds holding VCYT

Raymond James Financial's VCYT Position: Q3 2026 in Review

Raymond James Financial increased its Veracyte (VCYT) stake by 2.7% in Q3 2026, buying an estimated $604K and bringing the position to 484,821 shares worth $22.3M. The position accounts for 0.01% of the portfolio, ranked #1457.

Raymond James Financial first reported a position in VCYT in Q4 2024 and has held it in 8 quarters since. The position peaked at $27.7M in Q2 2026. 383 funds tracked by Wall St. Rank hold VCYT as of Q3 2026.

  • Raymond James Financial held 484,821 shares of Veracyte worth $22.3M as of Q3 2026.
  • Raymond James Financial bought 12,528 Veracyte shares in Q3 2026, an estimated $604K.
  • Veracyte made up 0.01% of Raymond James Financial's portfolio in Q3 2026, its #1457 holding.
  • Raymond James Financial first reported a position in Veracyte in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's Veracyte position peaked at $27.7M in Q2 2026.
  • 383 funds tracked by Wall St. Rank held Veracyte as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.